|
|
News Breaks | | | | September 30, 2012 | | 12:36 EDT |  | SNTA | Synta Galaxy 2b/3 trial results show promising survival improvement
Synta Pharmaceuticals announced results from an interim analysis of the Phase 2b portion of the GALAXY trial, a global, randomized, multi-center Phase 2b/3 study designed to evaluate the efficacy and safety of the company’s lead Hsp90 inhibitor, ganetespib, as second-line treatment for advanced non-small cell lung cancer, NSCLC. The results showed good tolerability for the combination of ganetespib and docetaxe, as well as meaningful improvements in overall survival, OS, in adenocarcinoma patients receiving docetaxel plus ganetespib compared to those receiving docetaxel alone. The results were presented by Suresh Ramalingam, MD, Professor, Hematology & Medical Oncology, and Director, Translational Thoracic Malignancies Program, of the Winship Cancer Institute of Emory University, in a poster session at the European Society for Medical Oncology 2012 Congress in Vienna, Austria. | |
|
News For SNTA From The Last 14 Days Check below for free stories on SNTA the last two weeks. |
|
|
| There are no results for SNTA |
|
|
|
|
|
|
